News Daily News FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis Michael O'Riordan May 01, 2025
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Daily News FDA Approves Portico TAVI Valve, Paving the Way for Third US Device Shelley Wood September 20, 2021
News Features Funding the Future: How Industry Support for CV Trials Could Evolve Michael O'Riordan December 17, 2020
News Conference News STS 2020 TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge Yael L. Maxwell January 29, 2020
News Daily News Sapien 3 Valve Approved in Europe for Low-Risk Patients Michael O'Riordan November 06, 2019
News Industry News Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System April 23, 2019
News Daily News LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR Yael L. Maxwell March 01, 2018
News Daily News FDA Expands CoreValve Indication to Include Intermediate-Risk Patients Michael O'Riordan July 10, 2017
News Daily News FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement Michael O'Riordan June 06, 2017
News Daily News FDA Approves 34-mm TAVR Valve for Patients With Larger Anatomy L.A. McKeown October 27, 2016
News Daily News Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe Michael O'Riordan September 20, 2016
News Daily News TAVR as an Option for Intermediate-Risk Patients: Physicians Respond Yael L. Maxwell August 24, 2016
News Daily News FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients Yael L. Maxwell August 18, 2016
News Daily News Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients Todd Neale August 01, 2016